Zusammenfassung
Auffälligste Entwicklung bei den Schlafmitteln ist der seit über 20 Jahren zu beobachtende starke Verordnungsrückgang um über 75%. Die Rückgänge betrugen im vergangenen Jahr bei den Benzodiazepinen 11%. Seit 2010 gehen auch die Verordnungen der Benzodiazepinagonisten Zolpidem und Zopiclon zurück, in 2013 um 5%. Dagegen haben die Verordnungen von Melatonin wiederum um über 10% zugenommen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
American Academy of Sleep Medicine (2005): The international classification of sleep disorders. 2nd Ed
Anonym (2007): Zolpidem (Stilnox u. a.): Schlafwandeln, „Schlafessen“ und „Schlaffahren“. Arzneitelegramm 38: 31–32
Becker HF, Mayer G, Penzel T (2004): Schlafstörungen und schlafbezogene Atmungsstörungen. Internist 45: 57–81
Bjorvatn B, Fiske E, Pallesen S (2011): A self-help book is better than sleep hygiene advice for insomnia: a randomized controlled comparative study. Scand J Psychol. 52: 580–585
Black JE, Brooks SN, Nishino S (2004): Narcolepsy and syndromes of primary excessive daytime somnolence. Semin Neurol 24: 271–282
Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I (2005): Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9: 41–50
Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP, Vohra S (2005): The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 20: 1151–1158
Cimolai N (2007): Zopiclone: is it a pharmacologic agent for abuse? Can Fam Physician 53: 2124–2129
Crestani F, Martin JR, Möhler H, Rudolph U (2000): Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 131: 1251–1254
Deutsche Gesellschaft für Neurologie (DGN) (2012a): S1-Leitlinie Restless-Legs-Syndrom (RLS) und Periodic Limb Movement Disorder (PLMD) http://www.awmf.org/leitlinien/detail/ll/030-081.html
Deutsche Gesellschaft für Neurologie (DGN) (2012b): S1-Leitlinie Insomnie http://www.awmf.org/leitlinien/detail/ll/030-045.html
Deutsche Gesellschaft für Neurologie (DGN) (2012c): S1-Leitlinie Narkolepsie http://www.awmf.org/leitlinien/detail/ll/030-056.html
Deutsche Gesellschaft für Schlafforschung und Schlafmedizin (DGSM) (2009): S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. Somnologie 13: 4–160. Internet: www.awmf.org/leitlinien/detail/ll/063-001.html
Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T (2004): Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 19: 305–322
European Medicines Agency (2007): Circadin. Europäischer öffentlicher Beurteilungsbericht (EPAR). Internet: www.emea.europa.eu/humandocs/PDFs/EPAR/circadin/H-695-en6.pdf
European Medicines Agency (2009/2011): Guideline on medicinal products for the treatment of insomnia. EMA/CHMP/16274/2009. Internet: www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500102351
Farkas RH, Unger EF, Temple R (2013): Zolpidem and driving impairment – identifying persons at risk. N Engl J Med 369: 689–691
Garcia-Borreguero D, Odin P, Schwarz C (2004): Restless legs syndrome: an overview of the current understanding and management. Acta Neurol Scand 109: 303–317
Glass JR, Sproule BA, Herrmann N, Streiner D, Busto UE (2003): Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol 23: 260–268
Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE (2005): Sedative hypnotics in older people with insomnia : meta-analysis of risks and benefits. Br Med J 331: 116–9
Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W (2003): Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98: 1371–1378
Happe S (2003): Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management. Drugs 63: 2725–2737
Haupt M, Cruz-Jentoft A, Jeste D (2006): Mortality in elderly dementia patients treated with risperidone. J Clin Psychopharmacol 26: 566–570
Herxheimer A (2005): Jet lag. Clin Evid 13: 2178–2183
Herxheimer A, Petrie KJ (2002): Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002; (2): CD001520
Hoffmann F, Glaeske G (2014): Benzodiazepinhypnotika, Zolpidem und Zopiclon auf Privatrezept. Nervenarzt (im Druck)
Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN (2012): Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ Dec 17;345: e834–3
Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW (2004): Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 164: 1888–1896
Klotz U (1995): Benzodiazepin-Hypnotika; Pharmakokinetik. In: Riederer P, Laux G, Pöldinger W (Hrsg): Neuropsychopharmaka, Bd 2. Springer-Verlag, Wien, S. 135–139
Kripke DF, Langer RD, Kline LE (2012): Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open. 2012 Feb 27;2(1):e00085–0
Lader M (1987): Clinical Pharmacology of Benzodiazepines. Ann Rev Med 38: 19–28
Lancee J, van den Bout J, van Straten A, Spoormaker VI (2012): Internet-delivered or mailed self-help treatment for insomnia?: a randomized waiting-list controlled trial. Behav Res Ther 50: 22–29
Lemoine P, Nir T, Laudon M, Zisapel N (2007): Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 16: 372–380
Mattila T, Stoyanova V, Elferink A, Gispen-de Wied C, de Boer A, Wohlfarth T (2011): Insomnia medication: do published studies reflect the complete picture of efficacy and safety? Eur Neuropsychopharmacol 21: 500–507
Ministry of Health and Social Policy (2009): Clinical practice guidelines for the management of patients with insomnia in primary care. Madrid. Internet: www.guiasalud.es/egpc/traduccion/ingles/insomnio/completa/
Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M (2003): Psychological treatment for insomnia in the management of long-term hypnotic drug use: a pragmatic randomised controlled trial. Br J Gen Pract 53: 923–928
Morin CM, Benca R (2012): Chronic insomnia. Lancet 379: 1129–1141
Morin CM, Bootzin RR, Buysse DJ, Edinger JD, Espie CA, Lichstein KL (2006): Psychological and behavioral treatment of insomnia. Sleep 29: 1398–1414
National Institute for Clinical Excellence, Technology appraisal guidance 77 (2004): Zaleplon, zolpidem and zopiclone for the short term management of insomnia. Internet: www.nice. org.uk/TA077
National Institutes of Health state of the science conference statement (2005): Manifestations and management of chronic insomnia in adults. Sleep 28: 1049–1057
Ohayon MM (2002): Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6: 97–111
Perlis ML, McCall WV, Krystal AD, Walsh JK (2004): Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 65: 1128–1137
Randall S, Roehrs TA, Roth T (2012): Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep. 35: 1551–1557
Riemann D, Hajak G (2009a): Insomnien. I. Ätiologie, Pathophysiologie und Diagnostik. Nervenarzt 80: 1060–1069
Riemann D, Hajak G (2009b): Insomnien. II. Pharmakologische und psychotherapeutische Behandlungsmöglichkeiten. Nervenarzt 80: 1327–1340
Roehrs TA, Randall S, Harris E, Maan R, Roth T (2012): Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol. 26: 1088–1095
Sack RL (2010): Clinical practice. Jet lag.N Engl J Med 362: 440–447
Sarris J, Byrne GJ (2011): A systematic review of insomnia and complementary medicine. Sleep Med Rev 15: 99–106
Sateia MJ, Nowell PD (2004): Insomnia. Lancet. 364: 1959–73
Schenck CH, Mahowald MW, Sack RL (2003): Assessment and management of insomnia. JAMA 289: 2475–2479
Schapira AH (2004): Restless legs syndrome: an update on treatment options. Drugs 64: 149–158
Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M (2008): Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 4: 487–504
Shen J, Chung SA, Kayumov L, Moller H, Hossain N, Wang X et al (2006): Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry 51: 27–34
Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, Schweitzer PK, Ware JC (2000): Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 23:1087–1096
Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, Frisher M (2014): Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014 Mar 19; 348: g1996. doi: 10.1136/bmj.g1996
Wiegand MH (2003): Arzneimittelbehandlung von Schlafstörungen im Alter. Internist 44: 1187–1192
Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, Britton TC, Crowe C, Dijk DJ, Espie CA, Gringras P, Hajak G, Idzikowski C, Krystal AD, Nash JR, Selsick H, Sharpley AL, Wade AG (2010): British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 24: 1577–1601
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
J. Lohse, M., Müller-Oerlinghausen, B. (2014). Hypnotika und Sedativa. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs- Report 2014. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43487-1_27
Download citation
DOI: https://doi.org/10.1007/978-3-662-43487-1_27
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-43486-4
Online ISBN: 978-3-662-43487-1
eBook Packages: Medicine (German Language)